What Is Tocilizumab (Actemra), and How Is It Used in Cancer Care?
Reading tools
In this article
Tocilizumab (Actemra)
An immune-modulating monoclonal antibody targeting the interleukin-6 receptor (IL-6R).
Target: IL-6R (sIL-6R & mIL-6R)
Administration: IV infusion
Brand: Actemra®
Summary
Drug Description
Tocilizumabblocks receptors for the proinflammatory cytokine interleukin-6, thereby suppressing excessive immune activation, reducing inflammation and relieving IL-6-mediated disease symptoms.
Mechanism of Action
Actemra, binds circulating (sIL-6R) and membrane-bound (mIL-6R) receptors, blocking IL-6 signaling. IL-6 is produced by many cells, including T/B cells, monocytes and fibroblasts, and is a proinflammatory cytokine.
Uses in Oncology
- Cytokine Release Syndrome (CRS) treatment
CAR-T or bispecific T-cell engagers → intense immune activation → excessive IL-6 release → risk of fever, hypotension, hypoxia and organ dysfunction.
Tocilizumab, through IL-6R blockade, rapidly stabilizes the response and controls CRS. (First FDA-approved drug for CRS) - CAR-T-Associated Neurotoxicity (ICANS)
Activity in ICANS is limited; usually combined with corticosteroids . - Research Areas
Studied for modulating chronic inflammation in the tumor microenvironment; not used as routine antitumor treatment.
Approved Non-Oncology Indications
- Rheumatoid arthritis (RA) – adults with inadequate DMARD response
- Giant cell arteritis (GCA) – adults
- Systemic sclerosis-associated interstitial lung disease (SSc-ILD) – slowing FVC decline
- PJIA & SJIA – age ≥2 years
- COVID-19 – approved in hospitalized adults receiving corticosteroids and needing supplemental oxygen/ventilation/ECMO; EUA for ages 2–<18
31 August 2017: The FDA approved Actemra for CAR-T-induced severe/life-threatening CRS treatment.
Country Information
Status in Turkey
- Licensing: Licensed in Turkey.
- Reimbursement: SGK coverage under specified rheumatology conditions. CRS may not have direct reimbursement; often supplied through off-label medication use authorization.
- Price: Actemra 200 mg/10 ml vial: 7.587.12 TL; Actemra 400 mg/20 ml vial: 15.064.35 TL; Actemra 80 mg/4 ml vial: 3.100.79 TL; Actemra 162 mg/0.9 ml, 4x 0.9 syringes: 16.472.97 TL.
Administration and Dosage
For CRS:Initial Dose (IV Only, 60-Minute Infusion):
• ≥30 kg: 8 mg/kg (per infusion, maximum 800 mg).
• <30 kg: 12 mg/kg.
• ≥30 kg: 8 mg/kg (per infusion, maximum 800 mg).
• <30 kg: 12 mg/kg.
Dose Adjustment (Repeat Dosing): After the first dose, if no clinical improvement occurs, allow ≥8 hours before repeating; maximum 4 doses in total (initial dose + up to 3 additional doses). The SC route is not approved for CRS; if necessary, corticosteroids may be added . For example, a 70 kg person receives 560 mg tocilizumab.
| Parameter | Recommendation |
|---|---|
| Administration Route | IV infusion |
| Adult Dose | 8 mg/kg (maximum single dose 800 mg) |
| Pediatric Dose | <30 kg: 12 mg/kg • ≥30 kg: 8 mg/kg |
| Repeat | If needed, 8 hours between doses; maximum 4 doses in 24 hours |
| Expected Effect | Fever/hypotension improves in most cases within hours ; usually 1–2 doses are sufficient |
CRS Initiation Criteria (NCCN & ASTCT)
| Grade | Clinical Status | Management |
|---|---|---|
| Grade 1 | Fever alone | Supportive care; tocilizumab usually unnecessary |
| Grade 2 | Hypotension controlled with fluids or a low O2 requirement |
Tocilizumab may be started |
| Grade 3–4 | Intensive care, high-dose vasopressors, severe hypoxia | Tocilizumab + if needed, corticosteroids |
Side Effects & Monitoring
- Increased Infection Risk: IL-6 suppression can cause CRP to fall; low CRP does not exclude infection.
- Laboratory Monitoring: Monitor liver function and hematological parameters with repeated doses.
- With ICANS: Tocilizumab alone is usually insufficient; corticosteroids may be added.
This summary supports clinical decisions; individualized management should follow current NCCN/ASTCT guidelines, institutional protocols and official product information.
✅ Quick Summary
- First-Line Biological Treatment: For moderate/severe CAR-T/bispecific-associated CRS.
- Dose: Adults 8 mg/kg (maximum 800 mg); repeat every 8 hours, maximum 4 doses in 24 hours.
- Effect: Clinical improvement within hours in most cases; usually 1–2 doses suffice.
- ICANS: Limited activity → add steroids.
- Turkey: Licensed; CRS usually requires off-label authorization.
Tocilizumab (Actemra®) in CRS — Drug Interactions & Clinical Points
🔹 Drug Interactions
- CYP450 enzyme activity ↑ → drug levels may fall.
- Warfarin, phenytoin, cyclosporine, tacrolimus, theophylline → efficacy may decrease.
- Statins, oral contraceptives, antifungals and some antiepileptics may be affected.
🔹 Clinical Precautions
- Infection Risk: TB/HBV reactivation, opportunistic infections.
- Laboratory: Monitor AST/ALT, neutrophils, platelets and lipids.
- Response Monitoring: Fever and CRP fall quickly → sepsis signs may be masked.
- Dosing: If the first dose fails, repeat after 8–12 hours; maximum 4 doses/28 days.
🔹 Other Points
- Live vaccines are contraindicated, particularly with prolonged use.
- Does not reduce the antitumor efficacy of CAR-T / BiTE treatments.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.